Expressions and Clinicopathologic Significances of CA19-9 and CA125 in Benign and Malignant Lesions of Gallbladder
Author(s): LIU Jie-qiong, YANG Zhu-lin, MIAO Xiong-yin
Pages: 92-95
Year: 2008 Issue: 2
Journal: CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY
Keyword: 胆囊腺癌; 慢性胆囊炎; 肿瘤标志物;
Abstract: 目的 研究胆囊腺癌及其癌旁组织和慢性胆囊炎组织中CA19-9和CA125表达水平并探讨其临床病理意义.方法 108例胆囊腺癌、46例癌旁组织和35例慢性胆囊炎手术切除标本常规石蜡包埋切片,应用EnVisionTM免疫组化法检测CA19-9和CA125的蛋白表达.结果 胆囊腺癌组织中CA19-9和CA125的表达阳性率(49.1%、 51.9%)明显高于癌旁组织(26.1%、15.2%)和慢性胆囊炎组织(14.3%、5.7%), P<0.01.腺瘤癌变、肿块最大径<2 cm、无淋巴结转移和未侵犯周围组织者CA19-9和CA125的表达阳性率均明显低于低分化腺癌、肿块最大径≥2 cm、有淋巴结转移和侵犯周围组织器官者(P<0.05,P<0.01); 两者在胆囊腺癌中的表达具有一致性(χ2=44.69,P<0.01).结论 CA19-9和CA125可能是反映胆囊腺癌发生、发展、生物学行为和预后的重要肿瘤标志物.
Pages: 92-95
Year: 2008 Issue: 2
Journal: CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY
Keyword: 胆囊腺癌; 慢性胆囊炎; 肿瘤标志物;
Abstract: 目的 研究胆囊腺癌及其癌旁组织和慢性胆囊炎组织中CA19-9和CA125表达水平并探讨其临床病理意义.方法 108例胆囊腺癌、46例癌旁组织和35例慢性胆囊炎手术切除标本常规石蜡包埋切片,应用EnVisionTM免疫组化法检测CA19-9和CA125的蛋白表达.结果 胆囊腺癌组织中CA19-9和CA125的表达阳性率(49.1%、 51.9%)明显高于癌旁组织(26.1%、15.2%)和慢性胆囊炎组织(14.3%、5.7%), P<0.01.腺瘤癌变、肿块最大径<2 cm、无淋巴结转移和未侵犯周围组织者CA19-9和CA125的表达阳性率均明显低于低分化腺癌、肿块最大径≥2 cm、有淋巴结转移和侵犯周围组织器官者(P<0.05,P<0.01); 两者在胆囊腺癌中的表达具有一致性(χ2=44.69,P<0.01).结论 CA19-9和CA125可能是反映胆囊腺癌发生、发展、生物学行为和预后的重要肿瘤标志物.
Citations
- Elevation of CA19-9 and chromogranin A,in addition to CA125,are detectable in benign tumors in leiomyomas and endometriosis Tsao KC Journal of Clinical Laboratory Analysis
- An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy Liu PY Journal of Clinical Oncology
- Reactivity of a monoclonal antibody with human ovarian carcinoma Bast RC Jr Journal of Clinical Investigation
- The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer Kang CM Journal of Surgical Research
- Tumor markers in patients with relapse of colorectal carcinoma Lipská L Anticancer Research
- Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer Bouanène H Bulletin Du Cancer
- Diagnostic value of serum CA242,CA19-9,CA15-3 and CA125 in patients with carcinoma of the gallbladder Shukla VK Tropical Gastroenterology
- Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes Nagao K International Journal of Urology
- Progress on molecular markers of pancreatic cancer Grote T Current Opinion in Gastroenterology
- 外周血糖链抗原CA50及CA19-9在大肠癌中的应用价值 杨风辉 中国普外基础与临床杂志
- 胰腺囊腺癌的诊断(附36例报告) 吴泓 中国普外基础与临床杂志
- Carcinomas of ovary and lung with clear cell features:can immunohistochemistry help in differential diagnosis? Howell NR International Journal of Gynecological Pathology
- Expression of WT1,CA 125,and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary Tornos C American Journal of Surgical Pathology
- Potential markers that complement expression of CA125 in epithelial ovarian cancer Rosen DG Gynecologic Oncology
- Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma Kushitani K Pathology International
- Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma Plemenos MF J BUON
- 卵巢癌和胰腺癌患者血清CA125、CA199的水平相关分析 王兰君 放射免疫学杂志
- CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish "MALOVA" Ovarian Cancer Study Hogdall EV Gynecologic Oncology
- ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer Locker GY Journal of Clinical Oncology
- Interchangeability of measurements of CA19-9 in serum with four frequently used assays:an update Passerini R Clinical Chemistry and Laboratory Medicine
Related Articles